Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Presentation is up

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Jan 21, 2022 9:27am

156 Views

Post# 34341619

RE:RE:RE:RE:RE:New Presentation is up

Thinking about the Last PR was from July I do recall Paul mentioning raising funds on a shareholder friendly basis a couple of times among others during last CC, but not sure it was anything mentioned before last July. So was this statement an attempt to reassure the shareholders who are worried about another round of too soon and give a way offering? Also they say they are currently dosing a number of patients(groups) when did that start this week or couple of months ago? We just don't know.

Wino115 wrote: Non-dilutive - we've heard it before from mgmt. Not sure it was in last presentation but probably was. It was what got some of us to look at those biotech alternative financing type of companies -- borrow now and pay later in royalties or convert to long-term debt. Some thought maybe factoring, but there's not enough in profits for that. So Pauls' been thinking non-dilutive for a while. Of course, the easiest is a straight partnering for the drug like many other's do. I still think it's a post-oncology news event as that opens up a better decision-tree for them.

scarlet1967 wrote:

“Currently dosing a number of additional patients at 420mg/m2”

So my guess they have stopped the single at a time patient dose escalation and moved to groups with the starting dose 420mg/m2.

Is the trial moving slowly? Not to me as it seems it’s on schedule based on what has been said since they started 10 months ago and each cycle can take 6 weeks they would have 6 or 7 cycles and that’s about it. And that’s not the end of the escalation if no DLT next stop is 560mg/m2 and so on. Of course a little bit more measured and clear communication would make it much easier for everyone to make their own educated guess.

I didn’t save the previous IP so the below could have been there but it does clearly say the NASH funding would be non-dilutive.

I personally feel better if it turns out to be true.

“In parallel, exploring other non-dilutive financing options to initiate trial prior to partnership finalization”